Meissa Vaccines, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
5
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
Phase 1
- Conditions
- Respiratory Syncytial Virus (RSV)
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Meissa Vaccines, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT04909021
- Locations
- 🇺🇸
MedPharmics, Metairie, Louisiana, United States
🇺🇸Paradigm Clinical Research, La Mesa, California, United States
🇺🇸The Emory Children's Center, Atlanta, Georgia, United States
Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults
Phase 1
- Conditions
- Covid19
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Meissa Vaccines, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT04798001
- Locations
- 🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States
🇺🇸Wake Research, Raleigh, North Carolina, United States
Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine
Phase 2
Completed
- Conditions
- RSV Infection
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Meissa Vaccines, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04690335
- Locations
- 🇬🇧
hVIVO Services Ltd, London, United Kingdom
Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Meissa Vaccines, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04444284
- Locations
- 🇺🇸
Meridian Clinical Research, Omaha, Nebraska, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Meissa Vaccines, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04227210
- Locations
- 🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States
News
No news found